Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
Hubei Goto Biopharm Co.Ltd. (300966) - Total Assets
Latest total assets as of September 2025: CN¥2.86 Billion CNY
Based on the latest financial reports, Hubei Goto Biopharm Co.Ltd. (300966) holds total assets worth CN¥2.86 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hubei Goto Biopharm Co.Ltd. - Total Assets Trend (2017–2024)
This chart illustrates how Hubei Goto Biopharm Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hubei Goto Biopharm Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Hubei Goto Biopharm Co.Ltd.'s total assets of CN¥2.86 Billion consist of 27.6% current assets and 72.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.1% |
| Accounts Receivable | CN¥216.31 Million | 7.8% |
| Inventory | CN¥384.80 Million | 13.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥49.88 Million | 1.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Hubei Goto Biopharm Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Goto Biopharm Co.Ltd.'s current assets represent 27.6% of total assets in 2024, a decrease from 62.0% in 2017.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2024, down from 9.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 13.8% of total assets.
Hubei Goto Biopharm Co.Ltd. Competitors by Total Assets
Key competitors of Hubei Goto Biopharm Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hubei Goto Biopharm Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hubei Goto Biopharm Co.Ltd. generates 0.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hubei Goto Biopharm Co.Ltd. is currently not profitable relative to its asset base.
Hubei Goto Biopharm Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.97 | 2.35 |
| Quick Ratio | 0.42 | 0.48 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥16.85 Million | CN¥ -23.68 Million | CN¥ 332.52 Million |
Hubei Goto Biopharm Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Hubei Goto Biopharm Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 14.0% |
| Total Assets | CN¥2.79 Billion |
| Market Capitalization | $169.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Goto Biopharm Co.Ltd.'s assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hubei Goto Biopharm Co.Ltd.'s assets grew by 14.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hubei Goto Biopharm Co.Ltd. (2017–2024)
The table below shows the annual total assets of Hubei Goto Biopharm Co.Ltd. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.79 Billion | +13.98% |
| 2023-12-31 | CN¥2.45 Billion | +18.34% |
| 2022-12-31 | CN¥2.07 Billion | +70.76% |
| 2021-12-31 | CN¥1.21 Billion | +50.57% |
| 2020-12-31 | CN¥804.43 Million | -1.62% |
| 2019-12-31 | CN¥817.68 Million | +32.94% |
| 2018-12-31 | CN¥615.08 Million | +27.26% |
| 2017-12-31 | CN¥483.34 Million | -- |